Comments
Loading...

Passage Bio Analyst Ratings

PASGNASDAQ
Logo brought to you by Benzinga Data
$12.87
-1.41-9.87%
At close: Jan 16, 4:00 PM EST
$12.75
-0.12-0.90%
After Hours: Jan 16, 4:24 PM EST
Consensus Rating1
Buy
Highest Price Target1
$67.00
Lowest Price Target1
$5.00
Consensus Price Target1
$25.00

Passage Bio Analyst Ratings and Price Targets | NASDAQ:PASG | Benzinga

Passage Bio Inc has a consensus price target of $25 based on the ratings of 6 analysts. The high is $67 issued by Canaccord Genuity on August 14, 2025. The low is $5 issued by Raymond James on November 14, 2023. The 3 most-recent analyst ratings were released by Chardan Capital, Canaccord Genuity, and Guggenheim on November 12, 2025, August 14, 2025, and August 14, 2025, respectively. With an average price target of $32.67 between Chardan Capital, Canaccord Genuity, and Guggenheim, there's an implied 156.12% upside for Passage Bio Inc from these most-recent analyst ratings.

Analyst Trends and Forecast

3
Aug 25
1
Nov 25
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Chardan Capital
Canaccord Genuity
Guggenheim
Wedbush
Rodman & Renshaw

1calculated from analyst ratings

Analyst Ratings for Passage Bio

Buy NowGet Alert
11/12/2025Buy Now64.65%Chardan Capital$6 → $21MaintainsBuyGet Alert
08/14/2025Buy Now425.3%Canaccord Genuity$260 → $67MaintainsBuyGet Alert
08/14/2025Buy Now-21.6%Guggenheim$40 → $10MaintainsBuyGet Alert
08/13/2025Buy Now213.61%Wedbush$3 → $40MaintainsOutperformGet Alert
06/24/2025Buy Now-52.96%Chardan Capital$6 → $6MaintainsBuyGet Alert
03/04/2025Buy Now-52.96%Chardan Capital$7 → $6MaintainsBuyGet Alert
11/29/2024Buy Now-68.64%Wedbush → $4Assumes → OutperformGet Alert
11/14/2024Buy Now-45.12%Chardan Capital$7 → $7MaintainsBuyGet Alert
11/14/2024Buy Now1.92%Canaccord Genuity$13 → $13MaintainsBuyGet Alert
09/17/2024Buy Now1.92%Canaccord Genuity$13 → $13ReiteratesBuy → BuyGet Alert
09/03/2024Buy Now-45.12%Rodman & Renshaw → $7Initiates → BuyGet Alert
05/15/2024Buy Now1.92%Canaccord Genuity$14 → $13MaintainsBuyGet Alert
03/05/2024Buy Now9.76%Canaccord Genuity → $14ReiteratesBuy → BuyGet Alert
12/21/2023Buy Now9.76%Canaccord Genuity$8 → $14MaintainsBuyGet Alert
11/14/2023Buy Now-60.8%Raymond James$9 → $5MaintainsOutperformGet Alert
08/08/2023Buy Now-29.44%Chardan Capital$11 → $9MaintainsBuyGet Alert
05/12/2023Buy Now-29.44%Raymond James$10 → $9MaintainsOutperformGet Alert

FAQ

Q

What is the target price for Passage Bio (PASG) stock?

A

The latest price target for Passage Bio (NASDAQ:PASG) was reported by Chardan Capital on November 12, 2025. The analyst firm set a price target for $21.00 expecting PASG to rise to within 12 months (a possible 64.65% upside). 6 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Passage Bio (PASG)?

A

The latest analyst rating for Passage Bio (NASDAQ:PASG) was provided by Chardan Capital, and Passage Bio maintained their buy rating.

Q

When was the last upgrade for Passage Bio (PASG)?

A

There is no last upgrade for Passage Bio

Q

When was the last downgrade for Passage Bio (PASG)?

A

There is no last downgrade for Passage Bio.

Q

When is the next analyst rating going to be posted or updated for Passage Bio (PASG)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Passage Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Passage Bio was filed on November 12, 2025 so you should expect the next rating to be made available sometime around November 12, 2026.

Q

Is the Analyst Rating Passage Bio (PASG) correct?

A

While ratings are subjective and will change, the latest Passage Bio (PASG) rating was a maintained with a price target of $6.00 to $21.00. The current price Passage Bio (PASG) is trading at is $12.75, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.